Elena Bruzzesi

Nov 19, 2024 | thelancet.com | Angelo Roberto Raccagni |Vita-Salute San Raffaele |Sara Diotallevi |Elena Bruzzesi

Bacterial sexually transmitted infections (STIs) are a considerable burden among people with HIV and users of HIV pre-exposure prophylaxis (PrEP).1–3 Doxycycline post-exposure prophylaxis (DoxyPEP) is a pharmacological intervention, the efficacy of which in reducing bacterial STIs, particularly syphilis and chlamydia, has been confirmed in several clinical trials.4–9 In this study, we aimed to evaluate the uptake of DoxyPEP among men who have sex with men (MSM) in Milan, Italy, its...

Jun 17, 2024 | sti.bmj.com | Angelo Roberto Raccagni |Elena Bruzzesi |Antonella Castagna |Silvia Nozza

Doxycycline postexposure prophylaxis may delay seroconversion in incident syphilis Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Dec 18, 2023 | mdpi.com | Angelo Roberto Raccagni |Elena Bruzzesi |Chiara Maci |Martina Ranzenigo

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Dec 18, 2023 | mdpi.com | Angelo Roberto Raccagni |Elena Bruzzesi |Chiara Maci |Martina Ranzenigo

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Jul 14, 2023 | liebertpub.com | Francesca Lombardi |Elena Bruzzesi |Yagaï Bouba |Domenico Di Carlo

AbstractDespite effective antiretroviral therapies (ARTs), a subset of people living with HIV (PLWH) still experience low-level viremia (LLV, i.e., 50–1,000 copies/mL). The present study compared PLWH experiencing LLV with those maintaining virological suppression (VS) and explored the potential impact of preexisting drug resistance and other factors on LLV.